Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15264617 | 0.98 | CCNB2 (0.34) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| Lithium Ion SCHEMBL15758974 | 0.95 | CCNB2 (0.33) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL30444986 | 0.71 | CHRNB2 (0.45) | — | |
| SCHEMBL166382 | 0.71 | MEN1 (0.38) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL30392892 | 0.71 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL17177076 | 0.71 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL108593 | 0.71 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL20168754 | 0.71 | CHRNB2 (0.45) | — | |
| SCHEMBL511354 | 0.70 | CCNB2 (0.34) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL113598 | 0.70 | CYP11B1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771330-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-09-26 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150322019-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-11-12 | — | — | US | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322019-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TYMP, TYMS, DPYD | CCNB2 67/4885CDK1 173/4885CCNB1 83/4885 |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, FLT3, TK1 | CCNB2 1148/4885CDK1 818/4885CCNB1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.